Table 1

Clinical features and treatment outcomes in American, German, and Japanese patients with autoimmune hepatitis with and without antibodies to soluble liver antigen/liver pancreas (SLA/LP) antigen

USAGermanyJapan
SLA/LP positive (n=23)SLA/LP negative (n=126)SLA/LP positive (n=21)SLA/LP negative (n=87)SLA/LP positive (n=2)SLA/LP negative (n=28)
*Statistical difference between SLA/LP positive (26 of 35) and SLA/LP negative (92 of 170) at p=0.02.
†Units in US patients in g/dl, in German and Japanese patients as relative per cent (%) of total serum protein (absolute values not available in all patients).
AST, aspartate aminotransferase; na, not available.
Values are mean (SEM) or number (%).
AST (U/ml) 442 (78) 507 (37) 186 (47) 275 (27) 51 (15.5) 227 (62)
γ-globulins† 3.1 (0.2) g/dl 3.1 (0.1) g/dl 27 (1.6) % 31 (1)% 34 (2)% 30 (1.9)%
Bilirubin (mg/dl) 4.9 (1.20) 4.1 (0.5) 3.4 (1.5) 3.6 (0.6) 0.8 (0.4) 2.5 (0.6)
Age at diagnosis (y) 43 (2) 46 (2) 41 (3) 46 (2) 48 (4) 54 (3.1)
Sex (M:F) 5:1826:1002:1911:760:22:26
Cirrhosis at diagnosis 7/23 (30%)33/124 (27%) 8/20 (40%)27/71 (38%) 0 na
Remission15/22 (68%)88/121 (73%) 21 (100%)67/81 (83%) na na
Relapse after remission15/15 (100%)* 64/88 (73%)*11/20 (55%)*28/82 (34%) * na na
Duration of symptoms (months) 38 (11) 27 (4) 35 (9) 26 (10) na na